Deal watch: Novartis acquires marketing rights for novel broad-spectrum antibiotic.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001424:Bacterial Infections / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D013754:Tetracyclines / Q000008:administration & dosage / Q000494:pharmacology*
C545884:7-dimethylamino-9-(2,2-dimethylpropyl)aminomethylcycline; D000900:Anti-Bacterial Agents; D013754:Tetracyclines